Breast Cancer Update
Dr. Neil Love
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
Episodes
Mentioned books
Dec 5, 2025 • 15min
Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.
Dec 2, 2025 • 17min
Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.
Nov 29, 2025 • 59min
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Dr Rinath M Jeselsohn and Dr Joyce O’Shaughnessy review current literature and datasets exploring the use of oral selective estrogen receptor degraders for the management of metastatic breast cancer. CME information and select publications here.
Nov 26, 2025 • 13min
Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.
Nov 20, 2025 • 59min
HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Dr. Erika Hamilton, a medical oncologist at Sarah Cannon Research Institute, dives into the cutting-edge world of PROTAC estrogen receptor degraders for HR-positive metastatic breast cancer. She breaks down the differences between PROTACs and traditional therapies like SERDs, detailing their unique mechanisms and resistance advantages. The conversation highlights clinical trial data, tolerability issues, and the importance of precise biomarker testing. Erika also shares insights on future applications and the evolving landscape of treatment strategies for this challenging disease.
Nov 14, 2025 • 2h 31min
ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDs
Prof Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, Dr Rebecca Shatsky from the University of California San Diego Moores Cancer Center and Dr Seth Wander from Massachusetts General Hospital in Boston discuss recent updates on available and emerging treatment strategies involving oral SERDs for ER-positive metastatic breast cancer. CME information and select publications here.
Nov 10, 2025 • 1h 58min
Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their perspectives on the evolving therapeutic landscape for patients with breast cancer. CME information and select publications here.
Nov 5, 2025 • 41min
ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer. CME information and select publications here.
Oct 27, 2025 • 16min
Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. CME information and select publications here.
Oct 21, 2025 • 57min
Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates
Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.CME information and select publications here.
